Future studies should focus on validating genes with clearer immunological relevance, such as HLA and STAT4, and narrowing the inclusion criteria to specific types of arthropathies more plausibly related to PPH risk. The gene discussed is STAT4; the disease is pulmonary arterial hypertension.